GlobeNewswire Inc | Nov 3, 2021 04:01PM EDT

November 03, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

Conference Call Information:

Date: Wednesday, November 10Time: 8:30 am Eastern TimeDomestic Dial-in: (844) 615-6509International Dial-in: (918) 922-3148Conference ID: 5783655Webcast: https://edge.media-server.com/mmc/p/zgrrmubx

About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Investor and Media Contact:Will BrownChief Financial OfficerPhone: 240-654-1450wbrown@altimmune.com